✦ LIBER ✦

Resolution of sexual dysfunction during acute treatment of major depression with milnacipran

✍ Scribed by David Baldwin; Ricardo A. Moreno; Mike Briley

Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 277 KB
Volume: 23
Category: Article
ISSN: 0885-6222
DOI: 10.1002/hup.955

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Objective

The sexual function and enjoyment questionnaire (SFEQ) was developed to assess and detect changes in sexual function in men and women. The aim of the present study was to use the SFEQ to evaluate the effects of the serotonin‐noradrenaline reuptake inhibitor, milnacipran, in the treatment of depression in two culturally different populations.

Methods

The SFEQ was employed in two studies investigating milnacipran in the treatment of major depression: a 12‐week open study in Brazil and a 6‐week randomised controlled study in Europe.

Results

At endpoint, 61.3% (Brazil) and 78.4% (Europe) of patients had ≥50% reduction of baseline Hamilton Depression Rating (HAMD) score. All SFEQ items showed improvements in sexual function in both studies at endpoint, 60% (Brazil) and 56% (Europe) of patients stating that their sexual desire was as great as or greater than it had been before their depressive episode.

Conclusions

Milnacipran appears to improve sexual function in parallel with improvement in other symptoms of depression. The SFEQ is a sensitive instrument for measuring changes in sexual function and appears to be unaffected by cultural differences as shown by similar findings in Brazil and Europe. Copyright © 2008 John Wiley & Sons, Ltd.

📜 SIMILAR VOLUMES

Milnacipran treatment of a terminally il

Milnacipran treatment of a terminally ill cancer patient with major depressive disorder

✍ Kazuhiro Sato; Hisashi Higuchi; Keizo Yoshida; Hitoshi Takahashi; Tetsuo Shimizu 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 36 KB 👁 1 views

Incidence and predictors of relapse duri

Incidence and predictors of relapse during continuation treatment of major depression with SSRI, interpersonal psychotherapy, or their combination

✍ Paola Rucci; Ellen Frank; Simona Calugi; Mario Miniati; Antonella Benvenuti; Mer 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB

Treatment-emergent suicidal ideation dur

Treatment-emergent suicidal ideation during 4 months of acute management of unipolar major depression with SSRI pharmacotherapy or interpersonal psychotherapy in a randomized clinical trial

✍ P. Rucci; E. Frank; P. Scocco; S. Calugi; M. Miniati; A. Fagiolini; G.B. Cassano 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB

A Double-Blind Comparison of Sertraline

A Double-Blind Comparison of Sertraline and Imipramine in Outpatients with Major Depression: Acute (8 Weeks) and Continuation (16 Weeks) Treatment

✍ J.-P. FOURNIER; R. M. LANE; G. CHOUINARD; D. B. WATSON; M. AMIN; R. A. REMICK; L 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 218 KB 👁 2 views

In a double-blind multicentre trial in patients with major depression, the ecacy and the tolerability of sertraline were compared to those of imipramine, during an 8-week acute treatment phase followed by a 16-week continuation treatment phase in treatment responders. A total of 104 patients who met

A double-blind, placebo-controlled asses

A double-blind, placebo-controlled assessment of nortriptyline's side-effects during 3-year maintenance treatment in elderly patients with recurrent major depression

✍ Rory L. Marraccini; Charles F. Reynolds III; Patricia R. Houck; Mark D. Miller; 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB 👁 2 views

The authors assessed the severity of nortriptyline's side-effects in older patients with recurrent major depression during placebo-controlled, double-blind maintenance therapy. Data were from 37 patients completing 2-3 years of maintenance therapy; 29 were on nortriptyline and eight were on placebo.